Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022

Rhea-AI Summary

Precision BioSciences, Inc. (Nasdaq: DTIL) has announced plans to publish its financial results for the third quarter of 2022 on November 8, 2022, along with a business update. The company focuses on developing ex vivo allogeneic CAR T and in vivo gene editing therapies using its proprietary ARCUS® genome editing platform. This platform is designed for therapeutic safety and versatility and aims to address genetic and infectious diseases lacking effective treatments.

Positive

• Announcement of financial results publication on November 8, 2022.
• Development of a proprietary ARCUS® genome editing platform, enhancing therapeutic safety.
• Focus on multiple CAR T immunotherapy clinical candidates and gene editing therapies.

Negative

• None.

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the third quarter 2022 and provide a business update on November 8, 2022.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221102005105/en/

Investor Contact:

Mei Burris

Director, Investor Relations and Finance

Mei.Burris@precisionbiosciences.com

Media Contact:

Maurissa Messier

Senior Director, Corporate Communications

Maurissa.Messier@precisionbiosciences.com

Source: Precision BioSciences, Inc.

FAQ

When will Precision BioSciences publish its Q3 2022 financial results?

Precision BioSciences will publish its Q3 2022 financial results on November 8, 2022.

What is the focus of Precision BioSciences?

Precision BioSciences focuses on developing CAR T immunotherapies and gene editing therapies using its ARCUS® platform.

What stock symbol is associated with Precision BioSciences?

The stock symbol for Precision BioSciences is DTIL.